During the last ten years our laboratory has attempted to understand ‘“how and why” HIV vaccines have failed in humans. Our studies were the first to demonstrate that two particular hormone-like molecules play an important role in modulating the “quality” of HIV-specific killer CD8 T cell immunity, in a vaccine delivery route dependent manner, where mucosal vaccination induced higher quality killer T cells compared to systemic vaccination (delivered to the blood compartment). Although HIV is first encountered at the mucosae, no mucosal vaccine strategy has yet entered into clinical trials. We have now designed two unique mucosal vaccine strategies that can transiently inhibit the activity of these molecules at the vaccination site, which results in “triple action immunity” (robust high quality HIV-specific mucosal/systemic killer T cells, and also excellent antibody immunity), similar to what has been reported in HIV elite controllers compared to non-controllers. We believe our triple action vaccine strategy provides good hope for the future.
The John Curtin School of Medical Research in conjunction with the ACT Branch of the Australian Society of Immunology, is hosting this lecture to coincide with World Day of Immunology, Wednesday 29 April.
Enquiries or to RSVP:
T 02 6125 2577
This lecture is free and open to the public
Seminar is followed by light refreshments in the foyer